132 related articles for article (PubMed ID: 33788556)
1. Imaging Somatostatin Positive Tumors with Tyr
Noor A; Van Zuylekom JK; Rudd SE; Roselt PD; Haskali MB; Yan E; Wheatcroft M; Hicks RJ; Cullinane C; Donnelly PS
Bioconjug Chem; 2021 Jul; 32(7):1192-1203. PubMed ID: 33788556
[TBL] [Abstract][Full Text] [Related]
2. Bivalent Inhibitors of Prostate-Specific Membrane Antigen Conjugated to Desferrioxamine B Squaramide Labeled with Zirconium-89 or Gallium-68 for Diagnostic Imaging of Prostate Cancer.
Noor A; Van Zuylekom JK; Rudd SE; Waldeck K; Roselt PD; Haskali MB; Wheatcroft MP; Yan E; Hicks RJ; Cullinane C; Donnelly PS
J Med Chem; 2020 Sep; 63(17):9258-9270. PubMed ID: 32786229
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic Positron Emission Tomography Imaging with Zirconium-89 Desferrioxamine B Squaramide: From Bench to Bedside.
Rudd SE; Noor A; Morgan KA; Donnelly PS
Acc Chem Res; 2024 May; 57(9):1421-1433. PubMed ID: 38666539
[TBL] [Abstract][Full Text] [Related]
4. Tumor uptake of 68Ga-DOTA-Tyr3-octreotate: animal PET studies of tumor flow and acute somatostatin receptor modulation in the CA20948 rat model.
Hanin FX; Pauwels S; Bol A; Breeman W; de Jong M; Jamar F
Nucl Med Biol; 2010 Feb; 37(2):157-65. PubMed ID: 20152715
[TBL] [Abstract][Full Text] [Related]
5. Fundamental study of radiogallium-labeled aspartic acid peptides introducing octreotate derivatives.
Ishizaki A; Mishiro K; Shiba K; Hanaoka H; Kinuya S; Odani A; Ogawa K
Ann Nucl Med; 2019 Apr; 33(4):244-251. PubMed ID: 30604401
[TBL] [Abstract][Full Text] [Related]
6. A desferrioxamine B squaramide ester for the incorporation of zirconium-89 into antibodies.
Rudd SE; Roselt P; Cullinane C; Hicks RJ; Donnelly PS
Chem Commun (Camb); 2016 Sep; 52(80):11889-11892. PubMed ID: 27711378
[TBL] [Abstract][Full Text] [Related]
7. In Vivo Evaluation of ¹⁸F-SiFAlin-Modified TATE: A Potential Challenge for ⁶⁸Ga-DOTATATE, the Clinical Gold Standard for Somatostatin Receptor Imaging with PET.
Niedermoser S; Chin J; Wängler C; Kostikov A; Bernard-Gauthier V; Vogler N; Soucy JP; McEwan AJ; Schirrmacher R; Wängler B
J Nucl Med; 2015 Jul; 56(7):1100-5. PubMed ID: 25977461
[TBL] [Abstract][Full Text] [Related]
8. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP
Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807
[TBL] [Abstract][Full Text] [Related]
9. Radiolabelling of the octadentate chelators DFO* and oxoDFO* with zirconium-89 and gallium-68.
Brandt M; Cowell J; Aulsebrook ML; Gasser G; Mindt TL
J Biol Inorg Chem; 2020 Aug; 25(5):789-796. PubMed ID: 32661784
[TBL] [Abstract][Full Text] [Related]
10. DOTA-D-Tyr(1)-octreotate: a somatostatin analogue for labeling with metal and halogen radionuclides for cancer imaging and therapy.
Li WP; Lewis JS; Kim J; Bugaj JE; Johnson MA; Erion JL; Anderson CJ
Bioconjug Chem; 2002; 13(4):721-8. PubMed ID: 12121126
[TBL] [Abstract][Full Text] [Related]
11. Preclinical evaluation of a high-affinity 18F-trifluoroborate octreotate derivative for somatostatin receptor imaging.
Liu Z; Pourghiasian M; Bénard F; Pan J; Lin KS; Perrin DM
J Nucl Med; 2014 Sep; 55(9):1499-505. PubMed ID: 24970911
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.
De Jong M; Valkema R; Jamar F; Kvols LK; Kwekkeboom DJ; Breeman WA; Bakker WH; Smith C; Pauwels S; Krenning EP
Semin Nucl Med; 2002 Apr; 32(2):133-40. PubMed ID: 11965608
[TBL] [Abstract][Full Text] [Related]
13. Rapid kit-based (68)Ga-labelling and PET imaging with THP-Tyr(3)-octreotate: a preliminary comparison with DOTA-Tyr(3)-octreotate.
Ma MT; Cullinane C; Waldeck K; Roselt P; Hicks RJ; Blower PJ
EJNMMI Res; 2015 Dec; 5(1):52. PubMed ID: 26452495
[TBL] [Abstract][Full Text] [Related]
14. Design, Synthesis, and Biological Evaluation of
Liu F; Liu T; Xu X; Guo X; Li N; Xiong C; Li C; Zhu H; Yang Z
Mol Pharm; 2018 Feb; 15(2):619-628. PubMed ID: 29278911
[TBL] [Abstract][Full Text] [Related]
15. Microscale radiosynthesis, preclinical imaging and dosimetry study of [
Lisova K; Sergeev M; Evans-Axelsson S; Stuparu AD; Beykan S; Collins J; Jones J; Lassmann M; Herrmann K; Perrin D; Lee JT; Slavik R; van Dam RM
Nucl Med Biol; 2018 Jun; 61():36-44. PubMed ID: 29747035
[TBL] [Abstract][Full Text] [Related]
16. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
[TBL] [Abstract][Full Text] [Related]
17. Peptide Receptor Radionuclide Therapy with
Cullinane C; Jeffery CM; Roselt PD; van Dam EM; Jackson S; Kuan K; Jackson P; Binns D; van Zuylekom J; Harris MJ; Hicks RJ; Donnelly PS
J Nucl Med; 2020 Dec; 61(12):1800-1805. PubMed ID: 32414949
[TBL] [Abstract][Full Text] [Related]
18. Two Novel Nanosized Radiolabeled Analogues of Somatostatin for Neuroendocrine Tumor Imaging.
Orocio-Rodríguez E; Ferro-Flores G; Santos-Cuevas CL; Ramírez Fde M; Ocampo-García BE; Azorín-Vega E; Sánchez-García FM
J Nanosci Nanotechnol; 2015 Jun; 15(6):4159-69. PubMed ID: 26369025
[TBL] [Abstract][Full Text] [Related]
19. Preliminary PET/CT Imaging with Somatostatin Analogs [
Satpati D; Shinto A; Kamaleshwaran KK; Sarma HD; Dash A
Mol Imaging Biol; 2017 Dec; 19(6):878-884. PubMed ID: 28349291
[TBL] [Abstract][Full Text] [Related]
20. Octreotide and octreotate derivatives radiolabeled with yttrium: pharmacokinetics in rats.
Laznicek M; Laznickova A; Mäcke HR; Eisenwiener K; Reubi JC; Wenger S
Cancer Biother Radiopharm; 2002 Oct; 17(5):527-33. PubMed ID: 12470422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
